List of Bylvay drug patents
Bylvay is owned by Albireo.
Bylvay contains Odevixibat.
Bylvay has a total of 9 drug patents out of which 1 drug patent has expired.
Expired drug patents of Bylvay are:
- US7132416
Bylvay was authorised for market use on 20 July, 2021.
Bylvay is available in capsule, pellets;oral, capsule;oral dosage forms.
Bylvay can be used as method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic), method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic), method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic).
Drug patent challenges can be filed against Bylvay from 2025-07-20.
The generics of Bylvay are possible to be released after 12 November, 2041.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7132416 | ALBIREO | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
Sep, 2022
(8 months ago) | |
| US10975046 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(16 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10487111 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(8 years from now) | |
| US10981952 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(8 years from now) | |
| US9694018 | ALBIREO | IBAT inhibitors for the treatment of liver disease |
Nov, 2031
(8 years from now) | |
| US10011633 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(8 years from now) | |
| US10093697 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(8 years from now) | |
| US11365182 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(16 years from now) | |
| US11583539 | ALBIREO | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors |
Nov, 2041
(18 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity (ODE) | Jul 20, 2028 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 2025-07-20
Market Authorisation Date: 20 July, 2021
Treatment: Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of treating pruritus in patients 3 months or older sufferi...
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
BYLVAY family patents
20
United States
7
European Union
6
Sweden
5
China
5
Japan
5
Hungary
4
Spain
4
Denmark
4
Poland
4
Brazil
4
Canada
4
Korea, Republic of
4
Israel
4
Portugal
4
Slovenia
4
Australia
4
Lithuania
3
Hong Kong
3
RS
3
United Kingdom
3
Singapore
3
Croatia
3
Mexico
3
Colombia
2
Philippines
2
Malaysia
2
Russia
2
Norway
2
Nicaragua
2
Cyprus
2
Peru
2
Chile
2
Taiwan
2
Jordan
2
Costa Rica
2
Ecuador
2
South Africa
1
Uruguay
1
Austria
1
Turkey
1
Iceland
1
Germany
1
Ukraine
1
Argentina
1
ME
1
New Zealand
1
San Marino
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic